Chiesi Global Rare Diseases and Protalix BioTherapeutics Confirm EMA Submission Approval for Pegunigalsidase Alfa Chiesi Global Rare Diseases and Protalix BioTherapeutics celebrate the validation from the EMA for a new dosing regimen of Pegunigalsidase Alfa, aimed at Fabry disease treatment.

Chiesi Global Rare Diseases and Protalix BioTherapeutics Confirm EMA Submission Approval for Pegunigalsidase Alfa #Italy #Chiesi_Global #Protalix_BioTherapeutics #Pegunigalsidase #Parma